

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	<b>ARGENICA THERAPEUTICS LIMITED</b>
<b>ABN</b>	<b>38 620 388 230</b>

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	LIZ DALLIMORE
<b>Date of last notice</b>	16 JUNE 2022

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	INDIRECT
<b>Nature of indirect interest (including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest.	TRUSTEE AND BENEFICIARY
<b>Date of change</b>	30 NOVEMBER 2022
<b>No. of securities held prior to change</b>	LEWIS MACDONALD DAWSON & ELIZABETH JANE DAWSON <DAWSON FAMILY A/C>  50,000 – FULLY PAID ORDINARY SHARES  2,500,000 – UNLISTED OPTIONS, EXERCISE PRICE \$0.30, EXPIRY DATE 30 SEP 2024
<b>Class</b>	UNLISTED OPTIONS
<b>Number acquired</b>	2,000,000

+ See chapter 19 for defined terms.

## Appendix 3Y

### Change of Director's Interest Notice

<b>Number disposed</b>	NIL
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	NIL
<b>No. of securities held after change</b>	<p>LEWIS MACDONALD DAWSON &amp; ELIZABETH JANE DAWSON &lt;DAWSON FAMILY A/C&gt;</p> <p>50,000 – FULLY PAID ORDINARY SHARES</p> <p>2,500,000 – UNLISTED OPTIONS, EXERCISE PRICE \$0.30, EXPIRY DATE 30 SEP 2024</p> <p>2,000,000 – UNLISTED OPTIONS, EXERCISE PRICE \$0.65, EXPIRY DATE 03 JUN 2025</p>
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	EMPLOYEE SHARE SCHEME OPTIONS APPROVED AT ANNUAL GENERAL MEETING

## Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

---

<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	N/A
<b>Interest after change</b>	N/A

**Part 3 – <sup>+</sup>Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	NO
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

---

<sup>+</sup> See chapter 19 for defined terms.